Back to Search
Start Over
Dolutegravir and weight gain: an unexpected bothering side effect?
- Source :
- AIDS. Official journal of the international AIDS Society, AIDS. Official journal of the international AIDS Society, 2017, 31 (10), pp.1499-1500. ⟨10.1097/QAD.0000000000001495⟩, AIDS, AIDS, Lippincott, Williams & Wilkins, 2017, 31 (10), pp.1499-1500. ⟨10.1097/QAD.0000000000001495⟩
- Publication Year :
- 2017
- Publisher :
- HAL CCSD, 2017.
-
Abstract
- We recently analyzed, in our real-life cohort of 2260 HIV-infected patients, the reasons for discontinuation of dolutegravir-based combined antiretroviral therapies (cARTs) [1]. Of 517 patients, 55 (10.6%) discontinued this cART due to adverse effects. Unexpectedly, four (7%) of these adverse effect
- Subjects :
- Male
0301 basic medicine
Cart
medicine.medical_specialty
Side effect
Pyridones
030106 microbiology
Immunology
Weight Gain
Piperazines
Cohort Studies
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Internal medicine
Oxazines
medicine
Humans
Immunology and Allergy
HIV Integrase Inhibitors
030212 general & internal medicine
Adverse effect
ComputingMilieux_MISCELLANEOUS
business.industry
virus diseases
Middle Aged
3. Good health
Discontinuation
Infectious Diseases
chemistry
Cohort
Dolutegravir
Female
medicine.symptom
business
Heterocyclic Compounds, 3-Ring
Weight gain
Cohort study
Subjects
Details
- Language :
- English
- ISSN :
- 02699370 and 14735571
- Database :
- OpenAIRE
- Journal :
- AIDS. Official journal of the international AIDS Society, AIDS. Official journal of the international AIDS Society, 2017, 31 (10), pp.1499-1500. ⟨10.1097/QAD.0000000000001495⟩, AIDS, AIDS, Lippincott, Williams & Wilkins, 2017, 31 (10), pp.1499-1500. ⟨10.1097/QAD.0000000000001495⟩
- Accession number :
- edsair.doi.dedup.....07becff3a7bfa6646f57b13f936e1be6